My feeling is that Wolgen is simply going to let the quarterly 4C's do the talking from now on.
Based on this 5 year old interview Wolgen expected eventual EPP sales of $100M p/year. That was when he thought the per implant price would be somewhere around the 5-7K mark (based on his remarks at the AGM in 2013).
http://news.trust.org//item/?map=interview-tiny-clinuvel-spurns-tanning-for-medical-need
Now that it has been confirmed that the implant is going to be 3-4 times that at 22K Euro, annual sales must now look like being north of $250M. That being the case this stock is one of the biggest no brainers available right now.
Finally after all these years the light at the end of the tunnel is starting to shine.
DYOR
Ann: SCENESSE launched in Europe-CUV.AX, page-4
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.12 |
Change
0.250(1.80%) |
Mkt cap ! $706.8M | |||
| Open | High | Low | Value | Volume |
| $13.90 | $14.17 | $13.90 | $675.2K | 48.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 293 | $14.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.12 | 261 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| CUV (ASX) Chart |